Thermo Fisher Scientific Inc. — FY2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; the supplied filing text does not provide a clear standalone fourth-quarter results summary.
Business context
Thermo Fisher serves pharmaceutical and biotechnology, academic and government, industrial, healthcare, and diagnostics markets. It reports four segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Biopharma Services. The 2022 results include the impact of the 2021 PPD acquisition, which contributed $7.11 billion of revenue in 2022.
Financial performance and liquidity
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $44.915 billion | $39.211 billion | +15% |
| Organic revenue growth | 0% | — | Acquisitions +18%; currency translation −3% |
| GAAP operating income | $8.393 billion | $10.028 billion | −16% |
| GAAP operating margin | 18.7% | 25.6% | −6.9 percentage points |
| Adjusted operating income | $10.985 billion | $12.138 billion | −9% |
| Adjusted operating margin | 24.5% | 31.0% | −6.5 percentage points |
| Net income attributable to Thermo Fisher | $6.950 billion | $7.725 billion | −10% |
| GAAP diluted EPS | $17.63 | $19.46 | −9% |
| Adjusted EPS | $23.24 | $25.13 | −8% |
| Operating cash flow | $9.154 billion | $9.312 billion | −2% |
| Free cash flow (non-GAAP) | $6.935 billion | $6.809 billion | +2% |
Segment results: Laboratory Products and Biopharma Services revenue was $22.511 billion (+51%), including PPD; Analytical Instruments was $6.624 billion (+9%); Life Sciences Solutions was $13.532 billion (−13%); and Specialty Diagnostics was $4.763 billion (−16%). Segment income margins were 12.8%, 22.8%, 41.2%, and 21.5%, respectively.
Balance sheet and capital: Cash and cash equivalents were $8.524 billion at year-end, versus total debt of $34.488 billion. Short-term debt was $5.579 billion. The $5.00 billion revolving credit facility had no borrowings outstanding, apart from immaterial letters of credit. The company repurchased $3.00 billion of stock and paid $455 million in cash dividends during 2022.
Material changes and management commentary
- Revenue increased primarily through acquisitions; organic revenue was flat. Currency translation reduced reported revenue by $1.35 billion.
- COVID-19 testing product revenue fell to $3.11 billion from $7.26 billion. Lower testing demand weighed on Life Sciences Solutions and Specialty Diagnostics.
- Management cited strong pharma and biotech demand, growth in academic and government markets, and robust industrial demand, particularly for analytical instruments serving semiconductor and materials-science customers.
- Lower COVID-19 testing volumes, strategic growth investments, acquisition impacts, and higher acquisition-related amortization reduced operating margins. Pricing and productivity gains partly offset these pressures.
- 2022 interest expense and other items included $26 million of debt-extinguishment losses and $160 million of net investment losses. The GAAP tax rate was 9.0%, including a $208 million net tax benefit related primarily to an IRS audit settlement; cash income taxes paid were $1.234 billion.
Outlook, risks and contingencies
- The filing gives no overall 2023 revenue or earnings guidance. Management expected COVID-19-related revenue to continue through 2023 but emphasized that its duration and scale were uncertain.
- For 2023, the company expected a GAAP effective tax rate of 7%–9%, an adjusted tax rate of approximately 11%, and capital expenditures of approximately $2.0 billion.
- Management stated that cash, expected operating cash flow, and available revolver capacity should meet existing-business cash requirements for at least the next 24 months. Debt agreements include a minimum 3.5:1 interest-coverage covenant.
- Key disclosed risks include economic and customer-spending cyclicality, inflation and supply constraints, foreign exchange, COVID-19-related demand uncertainty, competition, acquisition integration, cybersecurity and privacy, regulatory and quality compliance, and the ability to attract and retain talent.
- Environmental liabilities accrued were approximately $75 million. The accrual for product liability, workers’ compensation, and other personal-injury matters was $229 million, with estimated insurer recoveries of $95 million. The company noted that an unfavorable outcome exceeding current estimates could materially affect results, financial position, or cash flows.
- The company identified approximately $60 million of additional restructuring charges, primarily in 2023. It also reported $2.40 billion of unconditional purchase obligations, most expected to be settled during 2023.
- In January 2023, the company acquired The Binding Site for a reported purchase price of $2.71 billion, subject to final purchase-price allocation.
Important facts for investors to verify
- How much revenue and profit growth is achievable after the substantial COVID-19 testing decline, and how much FY2022 growth depended on acquisitions?
- Whether margins recover as acquisition integration progresses and strategic investments, inflation, and lower testing volumes affect costs.
- The company’s ability to meet the $5.579 billion of 2023 short-term debt maturities while maintaining its acquisition, investment, and shareholder-return plans.
- Whether management’s 2023 tax-rate and capital-expenditure expectations are realized, given the significant tax audit, valuation-allowance, and deferred-tax judgments disclosed.
- Potential changes in environmental, product-liability, restructuring, purchase-obligation, and acquisition-related exposures.
Adjusted results and free cash flow are non-GAAP measures; the company provides reconciliations in the filing. FY2022 reported revenue growth should be considered alongside flat organic growth and acquisition effects.